{"count":3,"limit":50,"offset":0,"edits":[{"id":46965,"actor_id":"codex:51","entity_type":"hypothesis","entity_id":"h-0b9e4152","action":"update","diff_json":{"after":0.62,"before":0.0},"change_reason":"Backfill data_support_score with cited empirical sources [task:2ab61458-7bb9-47d8-a7f2-c17802c60840]","created_at":"2026-04-26T21:44:07.424021+00:00"},{"id":46966,"actor_id":"codex:51","entity_type":"hypothesis","entity_id":"h-0b9e4152","action":"update","diff_json":{"after":"[data_support_backfill task:2ab61458-7bb9-47d8-a7f2-c17802c60840] data_support_score=0.620; evidence_component=0.42; kg_component=0.20; debate=0.10; analysis=0.10; contradiction_penalty=0.20; support_PMIDs=18599438,36834528,37095396,41935184,40139186,38589619 | contradicting_PMIDs=11081517,37690046,34103963,24951455 | kg_edges_generated=264;linked_KG=BDNF->SNAP25,promoted-h-0b9e4152,h-0b9e4152->ent-gene-4c050790 | analysis=SDA-2026-04-15-gap-pubmed-20260411-075338-35f913fb\nprior_evidence_validation={\"total_evidence\": 15, \"pmid_count\": 12, \"papers_in_db\": 2, \"description_length\": 3585, \"has_clinical_trials\": false, \"has_pathway_diagram\": true, \"has_gene_expression\": true, \"issues\": []}","before":"{\"total_evidence\": 15, \"pmid_count\": 12, \"papers_in_db\": 2, \"description_length\": 3585, \"has_clinical_trials\": false, \"has_pathway_diagram\": true, \"has_gene_expression\": true, \"issues\": []}"},"change_reason":"Backfill data_support_score with cited empirical sources [task:2ab61458-7bb9-47d8-a7f2-c17802c60840]","created_at":"2026-04-26T21:44:07.424021+00:00"},{"id":3461,"actor_id":null,"entity_type":"hypothesis","entity_id":"h-0b9e4152","action":"update","diff_json":{"after":"## MEF2C-Dependent Synaptic Gene Regulation in Neurodegeneration\n\n### MEF2C: A Master Regulator of Synaptic Plasticity\n\nMyocyte enhancer factor 2C (MEF2C) is a transcription factor highly expressed in neurons and critically involved in activity-dependent gene transcription that supports synaptic plasticity, learning, and memory formation. MEF2C acts as both activator and repressor depending on its cofactor context — in neurons, MEF2C typically activates synaptic gene programs while repressing inflammatory genes.\n\nMEF2C binds to MEF2 response elements (MARE sites) in target gene promoters. Key synaptic target genes include:\n- **BDNF (Brain-Derived Neurotrophic Factor):** Master regulator of synaptic strength and dendritic spine plasticity\n- **SYP (Synaptophysin):** Essential synaptic vesicle protein for neurotransmitter release\n- **SNAP25, SYNTAXIN:** Core SNARE complex components\n- **Arc (Activity-Regulated Cytoskeleton-associated Protein):** Critical for AMPA receptor trafficking and memory consolidation\n\nThe MEF2C transcriptional program is activity-regulated — neuronal depolarization increases MEF2C transcriptional activity, providing positive feedback where synaptic activity drives expression of genes that strengthen synaptic connections.\n\n### HDAC9 as a Negative Regulator of MEF2C\n\nHistone deacetylase 9 (HDAC9) is a class IIa HDAC highly expressed in the brain that acts as a transcriptional repressor by recruiting chromatin-remodeling complexes to MEF2C target gene promoters. HDAC9 binds to MEF2C and recruits HDAC3-containing co-repressor complexes.\n\nHDAC9 overexpression has been documented in AD brains and mouse models. Elevated HDAC9 levels correlate with reduced BDNF and synaptophysin expression, suggesting that HDAC9-mediated repression of the MEF2C synaptic gene program contributes to synaptic failure. STRING database confirms direct HDAC9-MEF2C physical interaction.\n\n### The Therapeutic Hypothesis\n\nThe hypothesis proposes that HDAC9 inhibition (or MEF2C activation) will restore the synaptic gene expression program and reverse synaptic failure. The therapeutic strategy has two complementary angles:\n\n**1. HDAC9 Inhibition:**\n- **Pharmacological:** Selective HDAC9 inhibitors (class IIa selective) block HDAC9's repressive activity without broadly affecting class I HDACs. Recent compounds with CNS penetration have shown promise.\n- **ASO-mediated:** Antisense oligonucleotides targeting HDAC9 mRNA provide sustained suppression with periodic dosing.\n- **Protein-protein interaction disruption:** Small molecules disrupting HDAC9-MEF2C interaction without inhibiting HDAC catalytic activity.\n\n**2. MEF2C Activation (Direct):**\n- **MEF2C agonists:** Small molecules enhancing MEF2C transcriptional activity by promoting coactivator recruitment.\n- **Gene therapy:** AAV-mediated MEF2C overexpression in targeted brain regions.\n\n### Evidence for the Synaptic Failure Cascade\n\nIn AD, multiple mechanisms lead to MEF2C dysfunction: tau pathology sequesters MEF2C; HDAC9 overexpression directly represses synaptic genes; epigenetic dysregulation globally suppresses expression; metabolic failure impairs sirtuin activity; inflammation suppresses BDNF through NF-κB competition.\n\n### Clinical Development\n\nThe therapeutic index of HDAC9 inhibition is favorable because partial inhibition is expected to be sufficient. HDAC9 knockout mice are viable and show cognitive enhancement without behavioral abnormalities. The challenge is achieving sufficient CNS penetration and target engagement in hippocampus and prefrontal cortex at tolerable doses.","before":"HDAC9 overexpression restores synaptic function through MEF2C-dependent transcriptional activation of neuroprotective genes (BDNF, SYP). STRING analysis confirms direct HDAC9-MEF2C interaction, and enrichment analysis shows HDAC9/MEF2C co-enrichment in synapse assembly and neuron survival pathways."},"change_reason":null,"created_at":"2026-04-16T17:18:16+00:00"}]}